Frequency Therapeutics Current Ratio 2018-2021 | FREQ

Frequency Therapeutics current ratio from 2018 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Frequency Therapeutics Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.17B $0.01B 19.09
2021-03-31 $0.20B $0.02B 10.58
2020-12-31 $0.23B $0.03B 8.45
2020-09-30 $0.23B $0.03B 6.91
2020-06-30 $0.20B $0.04B 4.82
2020-03-31 $0.21B $0.04B 4.80
2019-12-31 $0.22B $0.05B 4.19
2019-09-30 $0.17B $0.07B 2.31
2019-06-30 $0.00B 0.00
2019-03-31 $0.00B 0.00
2018-12-31 $0.00B 0.00
2018-09-30 $0.00B 0.00
2017-12-31 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.233B $0.037B
Frequency Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on harnessing the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company's lead product candidate, FX-322, is in clinical development and is designed to regenerate auditory hair cells to restore hearing function in patients with sensorineural hearing loss. Frequency Therapeutics Inc. is headquartered in Woburn, Mass.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86